By
Lisa Schnirring
Published: Jan. 10, 2019, 10:37 p.m.·
Tags:
Drug-resistant TB,
Treatment
A phase 3 trial of delamanid, a newer oral drug for treating multidrug-resistant tuberculosis (MDR-TB), found no statistically significant reduction in time to sputum culture conversion when compared to placebo, but that it was safe and well tolerated.
Read More →